news
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”
ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.
List view / Grid view
Therapeutics
news
Taletrectinib displays 90.5 percent objective response rate in NSCLC
Innovent Biologics and AnHeart Therapeutics jointly announced the interim clinical data from a Phase II trial (TRUST) evaluating taletrectinib (AB-106), an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive non-small cell lung cancer (NSCLC). The data was announced at the Chinese Society of Clinical Oncology (CSCO) 2021. Taletrectinib is an investigational next-generation…
news
Biological safety cabinet safest place for parenteral product compounding, says study
Researchers recommend the biological safety cabinet be used whenever possible to compound parenteral products in a clinical setting.
news
Lynparza® with abiraterone delays prostate cancer progression
Lynparza with abiraterone is the first PARP inhibitor to demonstrate clinical benefit in combination with a hormonal agent in this setting.
news
Babies with SMA able to swallow with Evrysdi® treatment
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
news
New radionuclides network to revolutionise nuclear medicine and molecular imaging
The European PRISMAP consortium will provide access to novel radioisotopes for medical research and promote the development of new radio-medicinal products.
news
Veklury® (remdesivir) reduces COVID-19 hospitalisation risk by 87 percent
Veklury (remdesivir) significantly reduced the risk of COVID-19 related hospitalisation and death in high-risk patients in Phase III study.
news
AstraZeneca to collaborate with VaxEquity on RNA therapeutics
AstraZeneca will partner with VaxEquity for the discovery and development of a self-amplifying RNA (saRNA) therapeutics platform.
news
Novartis acquires Arctos Medical to develop gene therapy programme
The Arctos Medical acquisition will expand Novarits’ optogenetics portfolio to bring gene therapies to patients with severe vision loss.
news
Xtandi® reduces prostate cancer death risk by 34 percent
Xtandi reduced the risk of death by 34 percent in men with metastatic hormone sensitive prostate cancer in a Phase III study.
news
EMA’s human medicines committee (CHMP) September meeting highlights
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
news
Kisqali® demonstrates longest overall median breast cancer survival
Kisqali plus letrozole achieved a median overall survival of over five years, the longest ever reported for HR+/HER2 breast cancer.
news
Trodelvy® improves breast cancer survival and quality of life
Trodelvy significantly improved overall survival and demonstrated clinically meaningful improvements in quality of life in Phase III study.
news
Sotorasib plus panitumumab shows efficacy against colorectal cancer
Sotorasib combined with panitumumab displayed 27 percent response rate against colorectal cancer in Phase I/II trial.
news
Ampion™ reduces severe knee osteoarthritis pain in 12 weeks
Ampion significantly reduced pain and improved function in severe osteoarthritis of the knee (OAK) in 12 weeks, shows Phase III study.
